Update app.py

app.py

@@ -20,6 +20,21 @@ REGRESSION_CONSTANTS = {
     }
 }
 
+# References content
+REFERENCES = [
+    "Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Miner Res. 2018;33(7):1219-1226. doi:10.1002/jbmr.3427",
+    "McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–1406.",
+    "McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass [published correction appears in Arch Intern Med. 2005 Oct 10;165(18):2120]. Arch Intern Med. 2005;165(15):1762-1768. doi:10.1001/archinte.165.15.1762",
+    "Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938. doi:10.1001/jama.296.24.2927",
+    "Black, D.M., et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 1996. 348(9041): p. 1535-41.",
+    "Harris, S.T., et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999. 282(14): p. 1344-52.",
+    "McClung, M.R., et al., Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med, 2001. 344(5): p. 333-40.",
+    "Reginster, JY., Minne, H., Sorensen, O. et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis. Osteoporos Int 11, 83–91 (2000).",
+    "Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249. doi:10.1359/JBMR.040325",
+    "10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension Bone, Henry G et al. The Lancet Diabetes & Endocrinology, Volume 5, Issue 7, 513 - 523.",
+    "Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):469-476. doi:10.1007/s00223-004-0039-7."
+]
+
 # Load medication data
 @st.cache_data
 def load_medication_data():
@@ -34,6 +49,12 @@ def calculate_bmd(bmd, percentage_increase):
 def calculate_tscore(bmd, mu, sigma):
     return (bmd - mu) / sigma
 
+# Display References
+def display_references():
+    with st.expander("References"):
+        for i, ref in enumerate(REFERENCES, start=1):
+            st.markdown(f"{i}. {ref}")
+
 # Generate prediction table for all drugs
 def generate_predictions(medication_data, site, bmd, mu, sigma):
     site_data = medication_data[medication_data['Site'] == site]
@@ -245,6 +266,8 @@ def main():
             # Display individual medication results
             display_results(filtered_predictions, selected_site)
 
-
+    # References always visible at the bottom
+    display_references()
+    
 if __name__ == "__main__":
     main()